Cargando…

Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3‐kinase dual inhibitor

Histone deacetylase (HDAC)/phosphatidylinositol 3‐kinase (PI3K) dual inhibition is a promising strategy for the treatment of intractable cancers because of the advantages of overcoming potential resistance and showing synergistic effects. Therefore, development of an HDAC/PI3K dual inhibitor is reas...

Descripción completa

Detalles Bibliográficos
Autores principales:	Saijo, Ken, Imai, Hiroo, Chikamatsu, Sonoko, Narita, Koichi, Katoh, Tadashi, Ishioka, Chikashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5497724/ https://www.ncbi.nlm.nih.gov/pubmed/28406576 http://dx.doi.org/10.1111/cas.13255

Ejemplares similares

In Vitro and in Vivo antitumor activity and the mechanism of siphonodictyal B in human colon cancer cells
por: Chikamatsu, Sonoko, et al.
Publicado: (2019)

LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK‐A11
por: Imai, Hiroo, et al.
Publicado: (2021)

Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
por: Saijo, Ken, et al.
Publicado: (2015)

Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells
por: Kawamura, Yoshifumi, et al.
Publicado: (2021)

Low Dose Histone Deacetylase Inhibitor, Depsipeptide (FR901228), Promotes Adenoviral Transduction in Human Rhabdomyosarcoma Cell Lines
por: Navid, Fariba, et al.
Publicado: (2004)

Histone deacetylase enzymes and selective histone deacetylase inhibitors for antitumor effects and enhancement of antitumor immunity in glioblastoma
por: Yelton, Caleb J., et al.
Publicado: (2018)

Inhibition of Topoisomerase II by a Novel Antitumor Cyclic Depsipeptide, BE‐22179
por: Yoshinari, Tomoko, et al.
Publicado: (1994)

Retrospective analysis on the clinical outcomes of recombinant human soluble thrombomodulin for disseminated intravascular coagulation syndrome associated with solid tumors
por: Ouchi, Kota, et al.
Publicado: (2018)

The G8 screening tool enhances prognostic value to ECOG performance status in elderly cancer patients: A retrospective, single institutional study
por: Takahashi, Masahiro, et al.
Publicado: (2017)

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs
por: Wang, Yuren, et al.
Publicado: (2017)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Development of Coumarin-Based Hydroxamates as Histone Deacetylase Inhibitors with Antitumor Activities
por: Zhao, Na, et al.
Publicado: (2020)

Histone Deacetylases (HDACs) and Atherosclerosis: A Mechanistic and Pharmacological Review
por: Chen, Xiaona, et al.
Publicado: (2020)

Suppression of FUT1 attenuates cell proliferation in the HER2-overexpressing cancer cell line NCI-N87
por: KAWAI, SADAYUKI, et al.
Publicado: (2012)

Design, synthesis, and antitumor evaluation of histone deacetylase inhibitors with l-phenylglycine scaffold
por: Zhang, Yingjie, et al.
Publicado: (2015)

Transcription inhibition by the depsipeptide antibiotic salinamide A
por: Degen, David, et al.
Publicado: (2014)

Applying molecular networking for targeted isolation of depsipeptides
por: Lin, Xiao, et al.
Publicado: (2021)

A Survey of Didemnin Depsipeptide Production in Tistrella
por: Stankey, Robert J., et al.
Publicado: (2023)

Interferon Regulatory Factor-8 Is Important for Histone Deacetylase Inhibitor-Mediated Antitumor Activity
por: Banik, Debarati, et al.
Publicado: (2012)

Antitumor Action of a Novel Histone Deacetylase Inhibitor, YF479, in Breast Cancer()
por: Zhang, Tao, et al.
Publicado: (2014)

Inhibition of Notch Signaling Enhances Antitumor Activity of Histone Deacetylase Inhibitor LAQ824
por: Mei, Qinglang, et al.
Publicado: (2023)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Efficacy of modified FOLFOX6 chemotherapy for patients with unresectable pseudomyxoma peritonei
por: Hiraide, Sakura, et al.
Publicado: (2019)

BRAF and MEK Inhibitor Treatment for Metastatic Undifferentiated Sarcoma of the Spermatic Cord with BRAF V600E Mutation
por: Saijo, Ken, et al.
Publicado: (2022)

High throughput RNAi screening identifies ID1 as a synthetic sick/lethal gene interacting with the common TP53 mutation R175H
por: IMAI, HIROO, et al.
Publicado: (2014)

Design and in silico screening of aryl allyl mercaptan analogs as potential histone deacetylases (HDAC) inhibitors
por: Singhal, Sugandha, et al.
Publicado: (2020)

Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
por: Imai, Yoichi, et al.
Publicado: (2016)

Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability
por: Milazzo, Giorgio, et al.
Publicado: (2020)

Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells
por: Okada, Kouji, et al.
Publicado: (2016)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

New histone deacetylase inhibitors improve cisplatin antitumor properties against thoracic cancer cells
por: Gueugnon, Fabien, et al.
Publicado: (2014)

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
por: Søgaard, Ole S., et al.
Publicado: (2015)

Marine Organisms as a Prolific Source of Bioactive Depsipeptides
por: Zeng, Mingyuan, et al.
Publicado: (2023)

Antibiotic therapy augments the efficacy of gemcitabine-containing regimens for advanced cancer: a retrospective study
por: Imai, Hiroo, et al.
Publicado: (2019)

Antibiotics Improve the Treatment Efficacy of Oxaliplatin-Based but Not Irinotecan-Based Therapy in Advanced Colorectal Cancer Patients
por: Imai, Hiroo, et al.
Publicado: (2020)

Depth of response may predict clinical outcome in patients with recurrent/metastatic head and neck cancer treated with pembrolizumab-containing regimens
por: Saijo, Ken, et al.
Publicado: (2023)

The Effects of Pharmacological Inhibition of Histone Deacetylase 3 (HDAC3) in Huntington’s Disease Mice
por: Jia, Haiqun, et al.
Publicado: (2016)

Dual targeting of retinoid X receptor and histone deacetylase with DW22 as a novel antitumor approach
por: Wang, Lihui, et al.
Publicado: (2015)

Purine analogs as phosphatidylinositol 4-kinase IIIβ inhibitors
por: Šála, Michal, et al.
Publicado: (2016)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_pkdlajk2bi6qn0omoqbopr0qc4